Targeted therapies have been developed for BRAF‐mutated melanoma, notably vemurafenib, which showed significant improvement in response rates and overall survival compared to traditional chemotherapy and became the first targeted standard of care for BRAF mutated melanoma (McArthur et al. 2014). This evidence concerns the gene BRAF and melanoma.